WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124470
CAS#: 2376629-15-9
Description: Zalunfiban (RUC-4) is a novel, subcutaneously administered glycoprotein IIb/IIIa inhibitor (GPI) designed for prehospital treatment to initiate reperfusion in the infarct-related artery (IRA) before primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction (STEMI).
Hodoodo Cat#: H124470
Name: Zalunfiban acetate
CAS#: 2376629-15-9
Chemical Formula: C18H22N8O4S
Exact Mass: 446.15
Molecular Weight: 446.490
Elemental Analysis: C, 48.42; H, 4.97; N, 25.10; O, 14.33; S, 7.18
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Zalunfiban acetate; RUC-4 acetate; Zalunfiban acetate [USAN]; 722PY2DT28; UNII-722PY2DT28;
IUPAC/Chemical Name: acetic acid;2-amino-N-[5-(5-oxo-7-piperazin-1-yl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)pyridin-3-yl]acetamide
InChi Key: UJGNATZMWUYIRZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H18N8O2S.C2H4O2/c17-7-13(25)20-11-5-10(8-19-9-11)15-22-24-14(26)6-12(21-16(24)27-15)23-3-1-18-2-4-23;1-2(3)4/h5-6,8-9,18H,1-4,7,17H2,(H,20,25);1H3,(H,3,4)
SMILES Code: CC(O)=O.O=C(NC1=CC(C(S2)=NN(C2=NC(N3CCNCC3)=C4)C4=O)=CN=C1)CN
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 446.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Rikken SAOF, Bor WL, Selvarajah A, Zheng KL, Hack AP, Gibson CM, Granger CB,
Bentur OS, Coller BS, van 't Hof AWJ, Ten Berg JM. Prepercutaneous coronary
intervention Zalunfiban dose-response relationship to target vessel blood flow
at initial angiogram in st-elevation myocardial infarction - A post hoc analysis
of the cel-02 phase IIa study. Am Heart J. 2023 Aug;262:75-82. doi:
10.1016/j.ahj.2023.04.009. Epub 2023 Apr 22. PMID: 37088164.
2: Rikken SAOF, Selvarajah A, Hermanides RS, Coller BS, Gibson CM, Granger CB,
Lapostolle F, Postma S, van de Wetering H, van Vliet RCW, Montalescot G, Ten
Berg JM, van 't Hof AWJ; CELEBRATE investigators. Prehospital treatment with
zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction
undergoing primary percutaneous coronary intervention: Rationale and design of
the CELEBRATE trial. Am Heart J. 2023 Apr;258:119-128. doi:
10.1016/j.ahj.2022.12.015. Epub 2022 Dec 31. PMID: 36592878.
3: Rikken SAOF, Storey RF, Andreotti F, Clemmensen P, Ten Berg JM. Parenteral
Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and
Future Directions. Thromb Haemost. 2023 Feb;123(2):150-158. doi:
10.1055/s-0042-1753479. Epub 2022 Sep 8. PMID: 36075236.
